Wednesday, 01 Apr 2020

You are here

RheumNow Podcast- A Good First Impression (1.24.20)

Dr Jack Cush comments on this week's journal articles, reviews and studies.

  1. Health Care Utilization prior to the Dx of Psoriatic Arthritis #PsA is significantly 2 fold higher. Study of 462 PsA & 2310 comparators shows more visits to PCP for MSK issues in 1-5 yrs prior, as well as use of other MSK specialists in 5 yrs preceding Dx. https://t.co/5729ya9Ahr
  2. Data from the Swedish Rheumatology Quality register (2716 RA pts) shows that biologic naive patients had longer drug survival. Men (HR 0.86) and MTX users (HR 0.85) were less likely to discontinue abatacept, https://t.co/Vhy3XtEg8R
  3. 60% The percentage of patients at @NIH's autoinflammatory disease cohort that are undifferentiated and do not have a specific disease diagnosis -Dr. Amanda Ombrello. #ACR19 @rheumnow https://t.co/d85OtnEA8o
  4. In 80 RA pts, SJC & TJC flares seen in 36% of pts. Pt-reported flares usually reflected incr Dz activity (MD exam & US). Pts & clinicians agreed in 79–93% of joints, moreso SJ than TJ   http://bit.ly/2NS2Fvk
  5. Population based study of ~72K chinese people shows that the DASH diet was assoc with significantly (30%) lower risk of hyperuricemia - more pronounced among older people (≥50 y), women and physically inactive (<0.01 for all). #Gout https://t.co/Ns1KzD5PfM
  6. IL-37 may be a target for psoriasis. IL-37 is downregulated in lesional skin & IL-37 serum levels correlate with psoriasis severity. IL-37 is an anti-inflammatory & immunosuppressive cytokine from IL-1 family. Tofacitinib may increase IL-37 in psoriasis https://t.co/jPaGlcDFV2
  7. Hydroxychloroquine in RA metanalysis shows clinical efficacy of HCQ was similar to or lower than MTX or SSZ monotherapy. When HCQ combined with other DMARDs it increased the clinical efficacy. There is a paucity of data on HCQ structural (Xray) benefits https://t.co/Q5ukHrjybJ
  8. A of TB risk with TNF inhib - Risks by country: - Worldwide - 9.62 cases/1000 pts exposed - Asia, 13.47 /1000 - S America 11.75 /1000 - Europe, 6.28 /1000 patients - North America 4.34 /1000 (low risk (USA, EU) and high risk countries (Asia, S.Amer). https://t.co/MNtnjbEuMS
  9. Anti-transcription intermediary factor 1 (TIF1)-γ autoantibodies are linked with cancer-associated Dermatomyositis in adults https://t.co/DeBoDdEbV1
  10. CDC: 15% of US Adults are Physically Inactive  
  11. Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

CDC: Impact of Underlying Health Conditions Among COVID-19 Patients

The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections.  Below are experts from that report.

TeleRheumatology - a TED Talk by Alvin Wells, MD

RheumNow Live 2020 featured a series of shorter STEP (TED-like) talks. This one features Dr. Alvin Wells discussing the opportunities and new paradigms encumbent with telemedicine in rheumatology.

RheumNow Podcast – New World Order (3.27.20)

Dr. Jack Cush reviews the news and COVID developments from this past week.

Global Rheumatology Alliance Registry Will Study COVID-19

In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.

RheumNow Podcast- COVID Siege (3.20.20)

Dr. Jack Cush reviews the past week of COVID-19 news and advances.